Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05829057
Other study ID # ZS205
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date May 23, 2023
Est. completion date June 21, 2025

Study information

Verified date February 2024
Source Zhejiang University
Contact weijia weijia
Phone 0086-571-87235144
Email weijiafang@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase Ia: single-dose escalation study: accelerated titration combined with traditional "3+3" dose. Sample size is correlated with the DLT occurring in each dose group. 4 dose groups are expected; the first dose group is the accelerated titration group, which includes only 1 subject; subsequent dose groups are in traditional "3+3" dose increments, with 3-6 subjects in each group; a total of 10-19 subjects are expected in all dose groups. If the DLT is still not present in the highest dose ,the safety monitoring committee(SMC) to determine if it is necessary to continue incrementally to a higher dose.


Description:

P-IL-2 injection was injected intravenously, the screening period was 28 days, and the DLT observation period was 28 days from the beginning of the first infusion (including the day of administration). After the end of the DLT observation period, subjects can continue to receive treatment on a voluntary basis. The safety follow-up after drug withdrawal was carried out 28 days after the last medication. During the survival follow-up after drug withdrawal, imaging examination and survival information were collected every 12 weeks as far as possible within 2 years after drug withdrawal, until the subjects developed disease or received other anti-tumor specific therapy. Subjects with disease progression or other treatment received telephone survival follow-up every 12 weeks. After 2 years of drug withdrawal, telephone survival follow-up was conducted every 12 weeks according to the wishes of the subjects.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date June 21, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Willing and able to follow study procedures , and sign a written informed consent form; 2. Males or females aged 18-75 years old at the time of signing the ICF; 3. Expected survival time = 12 weeks. 4. Physical condition score ECOG = 1. 5. There is still disease progression, intolerance or lack of effective standard treatment under standard treatment. Patients with advanced malignant solid tumor confirmed by pathology (recurrence and / or metastasis); at least 1 Measurable lesions in accordance with RECIST v1.1 or iRECIST standards. 6. Before the first administration, it had recovered from the toxic effects of the last treatment, and the researchers determined that the corresponding AE did not have a safety risk. 7. Organ and bone marrow function levels must meet the following requirements: Bone marrow: absolute neutrophil count (ANC) = 1.5 × 109 ppm L, specified value (according to Group determination, see Appendix 11 for instructions on platelet count during the screening period), platelets Count = 100x109 shock L, hemoglobin = 90g/L, and no blood transfusion within 14 days before the first administration. 8. Male subjects and female subjects of childbearing age from the signing of informed consent form to the end of drug research. Voluntary use of effective contraceptive measures within 5 months after secondary use. Exclusion Criteria: 1. Past or present suffering from other types of malignant tumors. 2. Known to be allergic to research drugs or any of their excipients, or to be too strict with other monoclonal antibodies.Severe anaphylaxis (NCI-CTCAE 5.0 grade = 3). 3. People have hemorrhagic diseases or have hemorrhagic tendencies. 4. Received any of the following treatments or drugs before the first study: - large surgery or severe trauma occurred within 4 weeks before the first study of drug treatment. - previous use of immunosuppressive drugs within 2 months prior to the first study, excluding nasal spray. - And inhaled corticosteroids or physiological doses of systemic steroids. - to study the Chinese medicine therapy with anti-tumor indications within 2 weeks before drug treatment for the first time. 5. Patients with a history of central nervous system metastasis (non-tumor meningeal metastasis) or spinal cord compression can be enrolled in the study if they have clearly received treatment and have stopped taking anticonvulsants and steroids for 4 weeks or more and have stable clinical manifestations before the first administration of the study. 6. Symptomatic, visceral spread, and short-term risk of life-threatening complications. the patients who underwent puncture and drainage within 3 weeks before the first administration included pleural effusion and abdominal cavity. Patients with effusion and pericardial effusion. 7. Subjects with active, or history of autoimmune diseases that may recur, or patients at high risk. subjects with the following diseases are allowed to join the group: - stable type I diabetic patients treated with fixed dose of insulin. - autoimmune hypothyroidism which only needs hormone replacement therapy. - skin diseases that do not require systemic treatment. - cured childhood asthma / allergy adult patients without any intervention. 8. Within 6 months before screening, any cardiovascular disease met any of the following criteria: - congestive heart failure with heart function = New York Heart Association (NYHA) Class II; left ventricular ejection. Blood fraction (LVEF) < 50%. - severe arrhythmias requiring drug treatment. - QTcF (Fridericia formula) male > 450ms, female > 470ms, or exist risk factors of apical torsion ventricular tachycardia are of clinical significance . - myocardial infarction and severe / unstable angina pectoris occurred within 6 months before administration. - history of thromboembolism with grade 3 or more in the past 2 years, or is being received because of a high risk of thrombosis. Receive thrombolytic or anticoagulant therapy. 9. Currently suffering from sudden lung disease, interstitial lung disease or pneumonia, pulmonary fibrosis, acute lung disease, etc., except local interstitial pneumonia caused by radiotherapy. 10. Uncontrolled systemic diseases . 11. history of human immunodeficiency virus infection, or suffer from other acquired, congenital immunodeficiency. Disease, or a history of organ transplantation, or a history of stem cell transplantation; 12. Evidence of active infection. 13. Previous history of neurological or mental disorders, or known history of psychotropic substance abuse and alcoholism. History or history of drug use. 14. Received any research drug within 4 weeks before the first administration, or participated in another clinical trial at the same time. 15. Female patients who are pregnant or lactating, or whose baseline pregnancy test results are positive. 16. The researchers believe that it is not suitable for patients to be included in this study.

Study Design


Intervention

Biological:
Intravenous injection of P-IL-2
Ia :Single dose intravenous injection of P-IL-2;
P-IL-2 plus Anti-PD-1 Monoclonal Antibody
Ib:P-IL-2 plus Anti-PD-1 Monoclonal Antibody;

Locations

Country Name City State
China First affiliated hospital, Zhejiang University Hangzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Zhejiang University Zcapsule Pharmaceuticals (Shaoxing) Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the number and severity of DLTs. DLT refers to toxicities that occur within 28 days of the subject's first dose and are judged by the investigator to be related to the study drug and meet the following conditions, including any =4 hematologic toxicity and non-hematologic toxicity. All toxicity or adverse events (AEs) are graded according to NCI-CTCAE 5.0. 28 days after infusion
Primary Incidence of AE and SAE Incidence and Severity of AE and SAE; An AE was any untoward medical occurrence after clinical study subjects receive study drug. An SAE was any event that meets any the following criteria: death, life-threatening; inpatient hospitalization or prolongation, persistent or significant disability/incapacity; congenital malformation/birth defects and significant medical events. AE and SAE were graded by CTCAE version 5.0 by severity, from Grade 1 mild to Grade 5 death related AE. 24 month after infusion
Primary Number of participants with physical examinations Make list of patients who were normal before administration and abnormal after administration, physical examinations includes general appearance and examinations of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, limbs, musculoskeletal system, nervous system and lymphatic system. 24 months after infusion
Secondary changes in the number of CD3+ cells relative to the baseline. Peripheral blood collection, number of CD3+ cells is detected by qPCR Within 28 days after infusion
Secondary changes of immunoglobulin IgG relative to the baseline. Peripheral blood collection, to monitor the changes of IgG Within 28 days after infusion
Secondary changes of immunoglobulin IgE relative to the baseline. Peripheral blood collection, to monitor the changes of IgE Within 28 days after infusion
Secondary changes of cytokines relative to the baseline Peripheral Blood collection,cytokines include IFN-??TNF-a?IL-2?IL-6?IL-10 Within 28 days after infusion
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2